# OnCo record vaginal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/vaginal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "vaginal" ;
  schema:name "Vaginal cancer"@en ;
  schema:alternateName "Vaginal squamous cell carcinoma"@en, "Primary vaginal carcinoma"@en, "VAIN (vaginal intraepithelial neoplasia; precursor)"@en ;
  schema:description "Primary vaginal cancer is rare and mostly caused by HPV, the virus behind cervical cancer. It is treated like cervical cancer, with weekly cisplatin alongside external and internal radiotherapy, which controls most tumours while preserving the organ; HPV vaccination and cervical screening, which also detects vaginal precursors, are steadily reducing it."@en ;
  schema:url <https://onco.cc/cancers/vaginal/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Vaginal_cancer> ;
  schema:citation <https://www.cancer.gov/types/vaginal>, <https://doi.org/10.1016/j.radonc.2023.109590>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1476>, <https://seer.cancer.gov/statfacts/html/vagina.html> ;
  onco:tag "nci-coverage", "rare", "gynaecologic", "hpv" ;
  onco:related <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/vulvar/>, <https://onco.cc/cancers/rhabdomyosarcoma/>, <https://onco.cc/cancers/anal/> ;
  onco:technologies <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/hpv-vaccine/>, <https://onco.cc/technologies/hpv-testing/>, <https://onco.cc/technologies/colposcopy-excision/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gardasil-9/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:pathways <https://onco.cc/pathways/oncogenic-viruses/> ;
  onco:terms <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/hpv-status/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/cin-hsil/> ;
  onco:trials <https://onco.cc/trials/keynote-826/>, <https://onco.cc/trials/keynote-a18/>, <https://onco.cc/trials/nct04422366/>, <https://onco.cc/trials/nct05027776/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-prevention-adoption/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-karius-radiother-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-a18/>, <https://onco.cc/technologies/hpv-vaccine/> ;
  onco:standardOfCare <https://onco.cc/technologies/hpv-testing/>, <https://onco.cc/technologies/colposcopy-excision/>, <https://onco.cc/technologies/precancer-ablation/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-826/> .